This paper is only available as a PDF. To read, Please Download here.
Abstract:
The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the model of antitumor therapy. With the continuous deepening of the research on the mechanism of immunotherapy, immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA4/CD28 inhibitors, have been widely used in a variety of tumors. However, the use of ICI can also lead to a series of immune-related adverse events (irAEs). Common immune-related adverse events include gastrointestinal toxicity, pulmonary toxicity, endocrine system toxicity, skin toxicity and so on. Neurological adverse events are relatively rare, but they seriously affect the quality of life and shorten the survival time of patients. This paper reports cases of peripheral neuropathy mediated by PD-1 inhibitors, and retrieves the relevant literatures at home and abroad to summarize the neurotoxicity caused by PD-1 inhibitors, so as to strengthen the awareness of clinicians and patients on neurological adverse reactions and mitigate potential adverse effects of implemented therapies.
Key words
Article info
Publication history
Accepted:
March 2,
2023
Received in revised form:
February 27,
2023
Received:
October 19,
2022
Publication stage
In Press Journal Pre-ProofFootnotes
Disclosure：The authors declare no conflict of interest.
CRediT AUTHOR STATEMENT：
Xia Zhang：Conceptualization， Methodology， Writing - Original Draft, Ming Gao：Investigation， Writing - Original Draft， Software, Binbin Sun：Supervision, Hongjun Hao：Supervision， Validation, Huan Yan： Resources, Chuntong Li： Supervision, Decong Sun： Investigation, Xuejiao Yang： Investigation, Yanfang Ju： Project administration， Visualization, Junxun Ma： Writing - Review & Editing
Identification
Copyright
© 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) | How you can reuse 
Elsevier's open access license policy
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy
